Equities research analysts expect Immatics (NASDAQ:IMTX – Get Rating) to announce earnings per share of $1.86 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Immatics’ earnings, with the lowest EPS estimate coming in at $1.65 and the highest estimate coming in at $2.07. Immatics posted earnings of ($0.41) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 553.7%. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Immatics will report full-year earnings of ($0.21) per share for the current financial year, with EPS estimates ranging from ($1.91) to $0.72. For the next year, analysts anticipate that the company will report earnings of ($1.77) per share, with EPS estimates ranging from ($2.32) to ($1.54). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Immatics.
A number of equities research analysts recently issued reports on IMTX shares. SVB Leerink lowered their target price on shares of Immatics from $32.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday, March 24th. Zacks Investment Research downgraded shares of Immatics from a “buy” rating to a “hold” rating in a research note on Friday, April 8th.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Woodline Partners LP raised its holdings in Immatics by 22.7% in the fourth quarter. Woodline Partners LP now owns 743,490 shares of the company’s stock valued at $9,993,000 after acquiring an additional 137,570 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Immatics in the 4th quarter valued at about $622,000. Sofinnova Investments Inc. lifted its position in shares of Immatics by 114.7% during the fourth quarter. Sofinnova Investments Inc. now owns 1,026,623 shares of the company’s stock worth $13,798,000 after purchasing an additional 548,407 shares during the last quarter. Marshall Wace LLP acquired a new position in Immatics in the fourth quarter worth about $41,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Immatics during the fourth quarter valued at approximately $163,000. 35.71% of the stock is currently owned by institutional investors and hedge funds.
About Immatics (Get Rating)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
- Get a free copy of the StockNews.com research report on Immatics (IMTX)
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.